1. "2014"
Formats
  1. Journal Article (2603)
  2. Meeting Abstract (1417)
  3. Book Section (235)
  4. Conference Paper (23)
  5. Book Whole (16)
  6. Review (3)
Groups
  1. Department of Medicine (1584)
  2. GSK Faculty (1082)
  3. Surgery (895)
  4. Solid Tumor Oncology Division (840)
  5. Center for Hematologic Malignancies (703)
  6. Sloan Kettering Institute Faculty (672)

More Groups

People
  1. Jedd Wolchok (71)
  2. Sergio Giralt (71)
  3. Ross Levine (69)
  4. Martin Tallman (62)
  5. Michael Berger (59)
  6. Mithat Gonen (55)

More People

Years
  1. 2014 (4297)
Publications
  1. Journal of Clinical Oncology (420)
  2. Blood (228)
  3. International Journal of Radiation Oncology, Biology, Physics (131)
  4. Cancer Research (104)
  5. Modern Pathology (89)
  6. Laboratory Investigation (82)

More Publications

Publishers
  1. Elsevier Inc. (495)
  2. American Society of Clinical Oncology (446)
  3. Springer (318)
  4. Elsevier Science, Inc. (246)
  5. Nature Publishing Group (242)
  6. American Society of Hematology (230)

More Publishers

Results (4297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Colorectal cancer
    Book Section

    Ruckel Kumar, J.; Winawer, S. J.; Zauber, A. G.
    In Senie, R. T. (Eds.) Epidemiology of Women's Health (2014)

    Fulltext@MSK | Save
  • Hospital business continuity
    Book Section

    Reissman, L.; Neufeld, J.
    In Fagel, M. J. (Eds.) Crisis Management and Emergency Planning: Preparing for Today's Challenges (2014)

    Fulltext@MSK | Save
  • Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Schaer, D.; Yang, X.; Zhong, H.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
    Meeting Abstract

    Holmgaard, R. B.; Zamarin, D.; Munn, D. H.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
    Meeting Abstract

    Budhu, S.; Schaer, D.; Li, Y.; Houghton, A.; Silverstein, S.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Brahmer, J.; Balmanoukian, A.; Goldberg, S.; Ou, S. H.; Blake-Haskins, A.; Karakunnel, J.; Stockman, P.; Rizvi, N.; Antonia, S.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)
    Meeting Abstract

    Page, D. B.; McArthur, H.; Dong, Z.; Wong, P.; Emerson, R.; Mu, Z.; Zhao, C.; Comstock, C.; Morris, E.; Comen, E.; more...
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorlyimmunogenic tumors
    Meeting Abstract

    Zamarin, D.; Holmgaard, R. B.; Plitt, T.; Allison, J.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Patterns of long-term survival following Ipilimumab (Ipi): The Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
    Meeting Abstract

    Page, D. B.; Naidoo, J.; Momtaz, P.; Bogatch, K.; Kuk, D.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Postow, M.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
    Meeting Abstract

    Hodi, F. S.; Ribas, A.; Daud, A.; Hamid, O.; Robert, C.; Kefford, R.; Hwu, W. J.; Gangadhar, T. C.; Joshua, A. M.; Hersey, P.; more...
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save